Skip to main content
Evidence Snapshot

Type-1 angiotensin II receptor

CHEMBL227 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T18:21:48Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL227
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Type-1 angiotensin II receptor as ChEMBL target CHEMBL227, mapped to UniProt P30556. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Type-1 angiotensin II receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL227
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30556
Type-1 angiotensin II receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Type-1 angiotensin II receptor matters

As of 2026-09-13

Type-1 angiotensin II receptor is reviewed as Type-1 angiotensin II receptor (UniProt P30556); Type-1 angiotensin II receptor shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.; 14 linked drugs keep this evidence frame grounded.; the current evidence base includes 19 approved drugs, 3352 compounds, and 320 assays, with lead potency reaching pChEMBL 10.9.

Disease context
hypertension

Type-1 angiotensin II receptor shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 14 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AZILSARTAN, AZILSARTAN KAMEDOXOMIL, CANDESARTAN.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include AZILSARTAN, AZILSARTAN KAMEDOXOMIL, CANDESARTAN, CANDESARTAN CILEXETIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 14 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 19 approved drugs, 3352 compounds, and 320 assays for this target. The dominant activity type is IC50. CHEMBL275875 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL275875 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
19 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Type-1 angiotensin II receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30556, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hypertension is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3352
Total Compounds
320
Total Assays
19
Approved Drugs
IC50: 1232.0, KI: 254.0, EC50: 293.0, KD: 25.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL275875
 10.9 Kd —
No preferred name
CHEMBL47177
 10.9 Kd —
No preferred name
CHEMBL346728
 10.3 IC50 —
No preferred name
CHEMBL305017
 10.0 IC50 —
No preferred name
CHEMBL70370
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
SPARSENTAN
CHEMBL539423
 2023
ANGIOTENSIN II
CHEMBL408403
 2017
TELMISARTAN
CHEMBL1017
 1998
IRBESARTAN
CHEMBL1513
 1997
EPROSARTAN
CHEMBL813
 1997
VALSARTAN
CHEMBL1069
 1996
LOSARTAN
CHEMBL191
 1995
LOSARTAN POTASSIUM
CHEMBL995
 1995
SARALASIN
CHEMBL938
 1982
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T18:21:48Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL227